CGEN
Price
$1.45
Change
-$0.03 (-2.03%)
Updated
Apr 28, 04:59 PM (EDT)
Capitalization
136.64M
9 days until earnings call
CYTK
Price
$41.19
Change
+$0.76 (+1.88%)
Updated
Apr 28, 04:59 PM (EDT)
Capitalization
4.91B
7 days until earnings call
Ad is loading...

CGEN vs CYTK

Header iconCGEN vs CYTK Comparison
Open Charts CGEN vs CYTKBanner chart's image
Compugen
Price$1.45
Change-$0.03 (-2.03%)
Volume$711
Capitalization136.64M
Cytokinetics
Price$41.19
Change+$0.76 (+1.88%)
Volume$35.77K
Capitalization4.91B
CGEN vs CYTK Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. CYTK commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a StrongBuy and CYTK is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (CGEN: $1.44 vs. CYTK: $41.22)
Brand notoriety: CGEN and CYTK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 26% vs. CYTK: 43%
Market capitalization -- CGEN: $136.64M vs. CYTK: $4.91B
CGEN [@Biotechnology] is valued at $136.64M. CYTK’s [@Biotechnology] market capitalization is $4.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $272.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 5 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s).

  • CGEN’s TA Score: 5 bullish, 4 bearish.
  • CYTK’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than CYTK.

Price Growth

CGEN (@Biotechnology) experienced а +3.60% price change this week, while CYTK (@Biotechnology) price change was +8.67% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.96%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -9.88%.

Reported Earning Dates

CGEN is expected to report earnings on Jul 31, 2025.

CYTK is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.91B) has a higher market cap than CGEN($137M). CGEN YTD gains are higher at: -5.882 vs. CYTK (-12.372). CGEN has higher annual earnings (EBITDA): -14.41M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. CGEN (103M). CGEN has less debt than CYTK: CGEN (2.91M) vs CYTK (789M). CGEN has higher revenues than CYTK: CGEN (27.9M) vs CYTK (18.5M).
CGENCYTKCGEN / CYTK
Capitalization137M4.91B3%
EBITDA-14.41M-493.48M3%
Gain YTD-5.882-12.37248%
P/E Ratio64.00N/A-
Revenue27.9M18.5M151%
Total Cash103M1.08B10%
Total Debt2.91M789M0%
FUNDAMENTALS RATINGS
CGEN vs CYTK: Fundamental Ratings
CGEN
CYTK
OUTLOOK RATING
1..100
1133
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9299
PRICE GROWTH RATING
1..100
8181
P/E GROWTH RATING
1..100
191
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CGEN's Valuation (50) in the Biotechnology industry is in the same range as CYTK (50). This means that CGEN’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (65) in the Biotechnology industry is somewhat better than the same rating for CGEN (100). This means that CYTK’s stock grew somewhat faster than CGEN’s over the last 12 months.

CGEN's SMR Rating (92) in the Biotechnology industry is in the same range as CYTK (99). This means that CGEN’s stock grew similarly to CYTK’s over the last 12 months.

CGEN's Price Growth Rating (81) in the Biotechnology industry is in the same range as CYTK (81). This means that CGEN’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is in the same range as CGEN (19). This means that CYTK’s stock grew similarly to CGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENCYTK
RSI
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 21 days ago
89%
Bearish Trend 7 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
80%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
75%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBMOX42.90N/A
N/A
Neuberger Berman Small Cap Growth Tr
VVPSX10.94N/A
N/A
Vulcan Value Partners Small Cap
CVMCX17.09N/A
N/A
Calvert Emerging Markets Equity C
FMIYX35.45N/A
N/A
FMI International Institutional
ILESX16.15N/A
N/A
Fisher IIG US Lrg Cp Eq Env & Scl Val

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-2.70%
NURPF - CGEN
46%
Loosely correlated
N/A
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
-3.86%
BDTX - CGEN
37%
Loosely correlated
+0.63%
BPMC - CGEN
37%
Loosely correlated
+0.97%
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+1.95%
IDYA - CYTK
48%
Loosely correlated
+3.95%
ACLX - CYTK
46%
Loosely correlated
+1.32%
KRYS - CYTK
46%
Loosely correlated
+0.99%
TRDA - CYTK
43%
Loosely correlated
+0.34%
DNLI - CYTK
43%
Loosely correlated
+3.64%
More